Andrew E. Levitt

Associate

Taft Law

Andrew Levitt is an associate in Taft’s Intellectual Property group. His practice includes patent prosecution, invalidity, and non-infringement opinions; prior art, clearance, and freedom-to-operate searches; as well as patent landscape studies, with a focus on biological sciences, pharmaceutical sciences, biochemistry, and biomedical instruments and methods. He also has experience handling clearance matters, as well as intellectual property transactions and licensing.

Prior to joining Taft, Andrew worked as patent counsel in the New York office of a well-known international firm.

Andrew earned his J.D. from William & Mary Law School where he graduated in the top 20% and was an articles editor for the William & Mary Bill of Rights Journal and the vice president of the Student Intellectual Property Society. He also completed research on lipid metabolism at Johns Hopkins University and earned his bachelor’s degree in biological sciences from George Washington University.

Recent Articles by Andrew E. Levitt

Amgen v. Sanofi: Seven Months In, Has Anything About Patent Enablement Changed?

Last term, the U.S. Supreme Court did something strange: the Court unanimously affirmed a circuit decision, which had unanimously affirmed a trial court decision. Little about the law seemed ripe for dispute or change, nevertheless, in Amgen v. Sanofi the Supreme Court spoke. Seven months later, innovators and patent practitioners are still scratching their heads. What impact, if any, does Amgen have? Is there a sign lower courts are interpreting Amgen as signaling a change in American patent law or did it merely ratify what already existed?

January 9, 2024

View All Posts